Clinical trials: Secondary Hyperparathyroidism, open to volunteers
Chronic Kidney Disease 5D, Secondary Hyperparathyroidism
A Observational Study to Evaluate the Efficacy and Safety of Pacitol Inj.
The purpose of this study is to evaluate the efficacy and safety of pacitol Inj.(paricalcitol) for secondary hyperparathyroidism with stage 5D chronic kidney disease (CKD 5D) receiving hemodialysis
- Trial name
- NCT06126016
- Where
- South Korea
- Volunteers
- 1,000 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Secondary Hyperparathyroidism
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in pediatric participants between ≥ 2 to < 18 years of age, with chronic…
- Trial name
- NCT03969329
- Testing
- Etelcalcetide
- Where
- 23 sites in Belgium, Czechia and 10 more
- Volunteers
- 24 people
- Sponsor
- Amgen
Lowering Parathyroid Hormone Level in Patients on Hemodioalysis
Comparative Effects of Doxercalciferol and Calcitriol on Secondary Hyperparathyroidism in ESRD
Secondary hyperparathyroidism (SHPT) is a common complication of advanced chronic kidney disease (CKD), caused by phosphate retention and vitamin D deficiency, leading to elevated parathyroid hormone (PTH) levels and increased…
- Trial name
- NCT07640347
- Testing
- Doxercalciferol administration, oral calcitriol 0.25 microgram
- Volunteers
- 98 people
- Sponsor
- Chittagong Medical College
Renal Osteodystrophy, Chronic Kidney Diseases
Precision Medicine Approaches to Renal Osteodystrophy
Treatment of renal osteodystrophy is impeded by the lack of practical and accurate tools to determine underlying bone turnover. Gold standard bone biopsy is not practical in the clinic for the vast majority of kidney disease…
- Conditions
- Renal Osteodystrophy, Chronic Kidney Diseases, CKD-MBD, Bone Turnover Rate Disorder
- Trial name
- PMaROD (NCT05880914)
- Testing
- miRNAseq analysis, Standard treatment for bone disorder
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Thomas Nickolas
Secondary Hyperparathyroidism Due to Renal Causes, End Stage Renal Failure
Retrospective Analysis of Quality of Life Changes in Patients Undergoing Parathyroidectomy for End-Stage Renal Disease
The purpose of this study is to characterize changes in quality of life in patients who had undergone parathyroidectomy for secondary hyperparathyroidism due to end-stage renal disease, based on data extracted from an established…
- Trial name
- NCT07151664
- Testing
- Quality of life progression after parathyroidectomy
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Parathyroid Tumor, Primary Hyperparathyroidism
Parathyroid Tumor Clonal Status
To define the frequency of monoclonal-X and polyclonal-X tumors in hyperparathyroid disorders patients having PTX and to define the relationship between parathyroid tumor clonal status and multiple gland neoplasia (MGN), we will…
- Conditions
- Parathyroid Tumor, Primary Hyperparathyroidism, Secondary Hyperparathyroidism (SHPT), Tertiary Hyperparathyroidism
- Trial name
- NCT05997810
- Where
- United States
- Volunteers
- 839 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Chronic Kidney Diseases, Hypertension
Integrated Diagnosis and Treatment of CKD on Outcomes
Objective: To establish a study cohort and follow up of patients with CKD in our hospital, and evaluate the status of integrated CKD diagnosis and treatment according to guidelines in the real world, as well as the clinical…
- Conditions
- Chronic Kidney Diseases, Hypertension, Hyperglycemia, Hyperlipidemias
- Trial name
- NCT05242055
- Testing
- Integrated diagnosis and treatment for CKD
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Capital Medical University
Hyperparathyroidism, Secondary, Kidney Failure, Chronic
Hyperparathyroidism and Dialysis Adequacy in Hemodialysis Patients
This cross-sectional study aims to determine the prevalence of secondary hyperparathyroidism among end-stage renal disease patients on regular hemodialysis and to evaluate its relationship with dialysis adequacy at Assiut…
- Conditions
- Hyperparathyroidism, Secondary, Kidney Failure, Chronic, Chronic Kidney Diseases
- Trial name
- NCT07820150
- Volunteers
- 130 people
- Sponsor
- Assiut University
AKI, CKD
Genetics in the Progression of Nephropathies
This study evaluates the role of genetic in the development and progression of different nephropaties with particular attention to: AKI CKD Hypertension ADPKD CKD-MBD Patients with decompensated heart failure undergoing either…
- Conditions
- AKI, CKD, Ckd-Mbd, CKD (Chronic Kidney Disease) Stage 5D
- Trial name
- NCT06416761
- Testing
- genetic polymorphisms
- Where
- Italy
- Volunteers
- 10,000 people
- Sponsor
- Ospedale San Raffaele
Achievement Rate, Efficacy and Safety
Thermal Ablation Versus Parathyroidectomy for Secondary Hyperparathyroidism
Secondary hyperparathyroidism (SHPT), which is frequently associated with chronic kidney disease, leads to problems such as bone pain, fractures, and cardiovascular issues, thereby affecting patients' quality of life.
- Conditions
- Achievement Rate, Efficacy and Safety, PTH, Calcium
- Trial name
- NCT06709586
- Testing
- Thermal ablation, parathyroidectomy
- Volunteers
- 612 people
- Sponsor
- Chinese PLA General Hospital
Vitamin D Deficiency Due to Chronic Kidney Disease
Vitamin D in Dialysis Patients - Diagnostic and Therapeutic Management
The goal of this observational study is to learn about the effects of cholecalciferol administration, according to guidelines for the general population, on laboratory parameters of Chronic Kidney Disease-Mineral and Bone…
- Trial name
- NCT06571344
- Testing
- Cholecalciferol
- Where
- Poland
- Volunteers
- 160 people
- Sponsor
- Medical University of Gdansk
Secondary Hyperparathyroidism, Chronic Kidney Disease
A Trial of Etelcalcetide in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
This is a phase 3 trial of etelcalcetide in pediatric participants with secondary hyperparathyroidism (SHPT) and chronic kidney disease (CKD) on hemodialysis.
- Trial name
- NCT03633708
- Testing
- Etelcalcetide, Standard of Care
- Where
- 43 sites in United States, Argentina and 8 more
- Volunteers
- 56 people
- Sponsor
- Amgen
Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis
Study of MT1013 Injection for the Treatment of Secondary Hyperparathyroidism (SHPT) Patients With Chronic Kidney Disease Undergoing Maintenance Dialysis
This is a multi-center, open, single-arm phase IIb clinical study comprising 2 parts, which Part A will enroll about 110 subjects, and Part B will enroll about 190 subjects to investigate long-term efficacy and safety of MT1013…
- Trial name
- NCT06976177
- Testing
- MT1013
- Where
- China
- Volunteers
- 310 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
Secondary Hyperparathyroidism;Parathyroidectomy
Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism
Total parathyroidectomy with autotransplantation (TPTX+AT) and Total parathyr- oidectomy alone (TPTX) are the common surgical procedures.The purpose of the study was to compare the long-term benefits of surgery between the two…
- Trial name
- NCT04922892
- Testing
- Parathyroidectomy
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The Second Hospital of Nanjing Medical University
End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis
Activated Charcoal Use in Chronic Kidney Disease Patients
Hyperphosphatemia management is initially based on restricting dietary phosphorus intake. Hyperphosphatemia is almost always seen in patients on dialysis and may contribute to progressive vascular calcification.
- Conditions
- End Stage Renal Disease (ESRD), CKD 5D, Hemodialysis, CKD-MBD - Chronic Kidney Disease Mineral and Bone Disorder
- Trial name
- NCT06906874
- Testing
- Activated Charcoal, Phosphate Binders
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Mansoura University
Chronic Kidney Disease (CKD), Secondary Hyperparathyroidism
A Study of PLS240 in Pediatric Participants With Secondary Hyperparathyroidism and Chronic Kidney Disease on Hemodialysis
Approximately 56 participants who are 1 month old to 17 years old will be enrolled in this study. The total duration for this study will be 38 weeks (or up to 42 weeks when participants require a washout period due to prior…
- Trial name
- NCT07890584
- Testing
- PLS240, Standard of Care
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Pathalys Pharma
Osteoporosis, Chronic Kidney Disease Mineral and Bone Disorder
Osteoporosis & Renal Disease: Research in Primary Health Care Services
Osteoporosis, a silent and multifactorial systemic skeletal disorder, severely compromises bone strength and significantly increases the risk of fragility fractures.
- Trial name
- NCT07848490
- Testing
- Fracture risk assessment tool (FRAX), Dual-Energy X-ray Absorptiometry (DXA)
- Where
- Portugal
- Volunteers
- 622 people
- Sponsor
- Universidade do Porto
Chronic Kidney Disease Mineral and Bone Disorder
The Effect of REgulation of PArathyroId hoRmone in Patients With Chronic Kidney Disease to Investigate the Change in Bone Mineral Density
The prevalence of chronic kidney disease (CKD) in the adult population is estimated to 10%. CKD increases risk of bone fractures, cardiovascular disease and death.
- Trial name
- REPAIR-CKD (NCT07171216)
- Testing
- Treat to target
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Herlev Hospital
Adynamic Bone Disease, Chronic Kidney Diseases
Treatment of Adynamic Bone Disorder With Parathyroid Hormone in Chronic Kidney Disease
This study is a 1:1 randomized controlled trial with an intervention for 18 months and a follow up period of 12 months. The purpose of the study is to assess the safety and efficacy of recombinant human parathyroid hormone for…
- Conditions
- Adynamic Bone Disease, Chronic Kidney Diseases, Cardiac Disease, Chronic Kidney Disease-Mineral and Bone Disorder
- Trial name
- NCT04522622
- Testing
- Teriparatide, DXA,VFA, X-ray, HR-pQCT, 18-F NAF PET/CT, Bone biopsy
- Where
- 4 sites in Denmark
- Volunteers
- 48 people
- Sponsor
- Ditte Hansen
Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function
REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial
This pilot randomized, open-label, outcome blinded clinical trial is to evaluate the preliminary effects of low-dose Colchicine (LoDoCo) on coronary artery calcification (CAC) progression in adults with chronic kidney disease…
- Conditions
- Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function, Vascular Calcification, Coronary Artery Calcification
- Trial name
- RESOLVE-CKD (NCT07654231)
- Testing
- Low-dose Colchicine at 0.5mg daily, Usual Care
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center